Opposition to IP protection for COVID-19 vaccines, therapies, tests and other technologies may only prevent eradication and treatment of the disease.
Kevin E. Noonan
Advertisement
Kevin E. Noonan, PhD, is a partner at McDonnell Boehnen Hulbert & Berghoff LLP.
Articles by Kevin E. Noonan
A controversial naming convention attempts to explain important distinctions between biologic drugs and their biosimilar counterparts.
Advertisement
Latest Updated Articles
Biosimilar Names Prove Difficult to DefinePublished: March 1st 2017 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
